ISCO
Price
$0.16
Change
-$0.00 (-0.00%)
Updated
Jun 26 closing price
Capitalization
1.26M
KNBIF
Price
$0.04
Change
-$0.00 (-0.00%)
Updated
Jun 24 closing price
Capitalization
6.68M
Interact to see
Advertisement

ISCO vs KNBIF

Header iconISCO vs KNBIF Comparison
Open Charts ISCO vs KNBIFBanner chart's image
International Stem Cell
Price$0.16
Change-$0.00 (-0.00%)
Volume$11.99K
Capitalization1.26M
Kane Biotech
Price$0.04
Change-$0.00 (-0.00%)
Volume$4K
Capitalization6.68M
ISCO vs KNBIF Comparison Chart in %
Loading...
ISCO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KNBIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ISCO vs. KNBIF commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ISCO is a StrongBuy and KNBIF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (ISCO: $0.16 vs. KNBIF: $0.04)
Brand notoriety: ISCO and KNBIF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ISCO: 205% vs. KNBIF: 6%
Market capitalization -- ISCO: $1.26M vs. KNBIF: $6.68M
ISCO [@Biotechnology] is valued at $1.26M. KNBIF’s [@Biotechnology] market capitalization is $6.68M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ISCO’s FA Score shows that 1 FA rating(s) are green whileKNBIF’s FA Score has 0 green FA rating(s).

  • ISCO’s FA Score: 1 green, 4 red.
  • KNBIF’s FA Score: 0 green, 5 red.
According to our system of comparison, ISCO is a better buy in the long-term than KNBIF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ISCO’s TA Score shows that 4 TA indicator(s) are bullish while KNBIF’s TA Score has 3 bullish TA indicator(s).

  • ISCO’s TA Score: 4 bullish, 3 bearish.
  • KNBIF’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, ISCO is a better buy in the short-term than KNBIF.

Price Growth

ISCO (@Biotechnology) experienced а +4.25% price change this week, while KNBIF (@Biotechnology) price change was -22.39% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KNBIF($6.68M) has a higher market cap than ISCO($1.26M). ISCO YTD gains are higher at: 92.989 vs. KNBIF (-54.545). ISCO has higher annual earnings (EBITDA): 111K vs. KNBIF (-3.7M). ISCO has more cash in the bank: 1.45M vs. KNBIF (494K). KNBIF has less debt than ISCO: KNBIF (2.08M) vs ISCO (4.1M). ISCO has higher revenues than KNBIF: ISCO (9.09M) vs KNBIF (2.44M).
ISCOKNBIFISCO / KNBIF
Capitalization1.26M6.68M19%
EBITDA111K-3.7M-3%
Gain YTD92.989-54.545-170%
P/E RatioN/A1.07-
Revenue9.09M2.44M372%
Total Cash1.45M494K294%
Total Debt4.1M2.08M197%
FUNDAMENTALS RATINGS
ISCO vs KNBIF: Fundamental Ratings
ISCO
KNBIF
OUTLOOK RATING
1..100
9250
VALUATION
overvalued / fair valued / undervalued
1..100
5
Undervalued
34
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4093
P/E GROWTH RATING
1..100
9094
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ISCO's Valuation (5) in the null industry is in the same range as KNBIF (34). This means that ISCO’s stock grew similarly to KNBIF’s over the last 12 months.

ISCO's Profit vs Risk Rating (100) in the null industry is in the same range as KNBIF (100). This means that ISCO’s stock grew similarly to KNBIF’s over the last 12 months.

ISCO's SMR Rating (100) in the null industry is in the same range as KNBIF (100). This means that ISCO’s stock grew similarly to KNBIF’s over the last 12 months.

ISCO's Price Growth Rating (40) in the null industry is somewhat better than the same rating for KNBIF (93). This means that ISCO’s stock grew somewhat faster than KNBIF’s over the last 12 months.

ISCO's P/E Growth Rating (90) in the null industry is in the same range as KNBIF (94). This means that ISCO’s stock grew similarly to KNBIF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ISCOKNBIF
RSI
ODDS (%)
Bearish Trend 4 days ago
89%
Bullish Trend 4 days ago
48%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
66%
Momentum
ODDS (%)
Bullish Trend 4 days ago
82%
Bearish Trend 4 days ago
71%
MACD
ODDS (%)
Bullish Trend 4 days ago
74%
Bullish Trend 4 days ago
68%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
72%
Bearish Trend 4 days ago
64%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
73%
Bearish Trend 4 days ago
63%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
83%
Aroon
ODDS (%)
N/A
Bearish Trend 4 days ago
72%
View a ticker or compare two or three
Interact to see
Advertisement
ISCO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KNBIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PDM7.280.18
+2.54%
Piedmont Realty Trust Inc
CGTX0.30N/A
N/A
Cognition Therapeutics
FANG139.77-1.10
-0.78%
Diamondback Energy
STNG40.42-0.50
-1.22%
Scorpio Tankers
HBIO0.46-0.05
-9.44%
Harvard Bioscience

ISCO and

Correlation & Price change

A.I.dvisor tells us that ISCO and XBIT have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ISCO and XBIT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ISCO
1D Price
Change %
ISCO100%
N/A
XBIT - ISCO
29%
Poorly correlated
-2.44%
INDP - ISCO
22%
Poorly correlated
+3063.04%
CORT - ISCO
21%
Poorly correlated
-1.49%
BLTE - ISCO
20%
Poorly correlated
-1.44%
IGXT - ISCO
9%
Poorly correlated
N/A
More

KNBIF and

Correlation & Price change

A.I.dvisor tells us that KNBIF and CCCC have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that KNBIF and CCCC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KNBIF
1D Price
Change %
KNBIF100%
N/A
CCCC - KNBIF
21%
Poorly correlated
-7.89%
MMIRF - KNBIF
12%
Poorly correlated
N/A
IGXT - KNBIF
7%
Poorly correlated
N/A
ISCO - KNBIF
5%
Poorly correlated
N/A
INTI - KNBIF
4%
Poorly correlated
-2.09%
More